Politics / Law

Biofuels – a step in the right direction

22.08.2011

In June, the European Commission presented the first EU certification schemes designed to certify that biofuels marketed in the EU are produced from sustainable resources. The approval of these voluntary schemes is excellent news for the industry, as it provides guarantees on environmental sustainability. However, regulatory uncertainties still remain on ad hoc sustainability issues. These must be resolved quickly to maximise the potential offered by sustainable biofuels.

The seven voluntary certification schemes approved thus far have been introduced to support the implementation of sustainability criteria for biofuels, a requirement of the EU’s Renewable Energy Directive (RED). The schemes provide a practical implementation of the mandatory sustainability criteria, and ensure that only sustainable biofuels will contribute towards the RED target of 10% renewable energy in transport by 2020.
The approval of the first batch of EU certification schemes should help address growing concerns associated with biofuels, and they have the advantage of providing certification that is applicable across the whole European market. Industry has indicated a willingness to demonstrate compliance with the RED sustainability criteria, and the new schemes now make this possible. EU approval is also very important for Member States, which have been waiting to clarify the implementation of certification procedures before embarking on additional efforts to incorporate biofuels. The absence of certification schemes is one reason why growth in European biofuels consumption lost momentum last year.
The certification schemes position Europe as a global front-runner in promoting sustainable biofuels. This will hopefully provide a boost for top-performing products, including advanced biofuels. How­ever, we should not underestimate the efforts required for industry to implement the sustainability criteria. The approval is clearly a step in the right direction, but it won’t solve all of the sustainability issues.
Regulatory issues also still need to be clarified. The debate surrounding indirect Land Use Change (iLUC) has generated a lot of uncertainty, and has delayed investments in advanced biofuels plants. Forming a coherent policy on iLUC is challenging, because its effects are hard to quantify. But to end the market uncertainty, the European Commission must come to a conclusion soon. Any decision should be both easily implementable and stable. It should also promote the best performing biofuels available and the fast deployment of advanced biofuels. Only when this regulatory gap is closed will Europe start to reap the benefits sustainable biofuels can bring.
Europe should also be looking at the role advanced biofuels can play beyond the transport fuel sector. Biocomponents are the only sustainable alternative to fossil fuels in the production of chemicals, plastics or textiles. Advanced biofuels deployment is therefore a first step towards a sustainable bio-based society.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/biofuels-a-step-in-the-right-direction.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SUMMIT (UK)4.03 GBP3.87%
  • DEINOVE (F)13.32 EUR2.46%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • CELLECTIS (F)13.54 EUR112.6%
  • ADDEX (CH)4.54 CHF108.3%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-42.9%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 13.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events